US News in English<p>Mereo BioPharma reports 2024 financial results and advances rare disease pi... - published 26 Mar 2025 <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <a href="https://mastodon-grafa.social/tags/Grafa" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grafa</span></a> <a href="https://mastodon-grafa.social/tags/DeFi" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>DeFi</span></a> <br><a href="https://grafa.com/news/health-mereo-biopharma-reports-2024-financial-results-and-advances-rare-disease-pipeline-406834?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=406834" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-mereo-bi</span><span class="invisible">opharma-reports-2024-financial-results-and-advances-rare-disease-pipeline-406834?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=406834</span></a></p>
Recent searches
No recent searches
Search options
Only available when logged in.
mstdn.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
A general-purpose Mastodon server with a 500 character limit. All languages are welcome.
Administered by:
Server stats:
16Kactive users
mstdn.social: About · Status · Profiles directory · Privacy policy
Mastodon: About · Get the app · Keyboard shortcuts · View source code · v4.3.4
#clinicaltrials
20 posts · 15 participants · 2 posts today
IQWiG<p>What to do if <a href="https://wisskomm.social/tags/PubMed" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>PubMed</span></a> goes down the drain </p><p>The news from the US is unsettling, not least for medical information specialists. Siw Waffenschmidt, Head of our Department of Information Management, asks <span class="h-card" translate="no"><a href="https://mastodon.online/@hildabast" class="u-url mention" rel="nofollow noopener noreferrer" target="_blank">@<span>hildabast</span></a></span>, author of the blog 'Absolutely Maybe' and former NIH employee, for an assessment of the situation regarding PubMed and <a href="https://wisskomm.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a>.gov. How can all of us prepare for possible PubMed downtimes or deficiencies?</p><p><a href="https://youtu.be/fn2paCE6Zco?si=atNcEhzfP3Ptbuuk" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">youtu.be/fn2paCE6Zco?si=atNcEh</span><span class="invisible">zfP3Ptbuuk</span></a></p>
ASX Mkt. Sensitive<p>4Dmedical ( <a href="https://mastodon-grafa.social/tags/4DX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>4DX</span></a> ) has released " Cost reduction program delivers $6.5m in annualised savings " on Wed 26 Mar at 09:58 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/tax" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>tax</span></a> <a href="https://mastodon-grafa.social/tags/ArtificialIntelligence" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ArtificialIntelligence</span></a> <a href="https://mastodon-grafa.social/tags/NYSE" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NYSE</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <br><a href="https://grafa.com/asset/4dmedical-ltd-5186-4dx.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=4dx.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/4dmedical-ltd-</span><span class="invisible">5186-4dx.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=4dx.asx</span></a></p>
ASX News in English<p>Prescient Therapeutics launches first clinical site for PTX-100 Phase 2a st... - published 25 Mar 2025 <a href="https://mastodon-grafa.social/tags/UnitedStates" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStates</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <br><a href="https://grafa.com/news/health-prescient-therapeutics-launches-first-clinical-site-for-ptx-100-phase-2a-study-in-ctcl-treatment-406013?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=406013" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-prescien</span><span class="invisible">t-therapeutics-launches-first-clinical-site-for-ptx-100-phase-2a-study-in-ctcl-treatment-406013?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=406013</span></a></p>
ASX Mkt. Sensitive<p>Clinuvel Pharmaceuticals ( <a href="https://mastodon-grafa.social/tags/CUV" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>CUV</span></a> ) has released " Positive preliminary results for PRENUMBRA Instant in stroke " on Wed 26 Mar at 09:15 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/tax" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>tax</span></a> <a href="https://mastodon-grafa.social/tags/government" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>government</span></a> <a href="https://mastodon-grafa.social/tags/China" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>China</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <br><a href="https://grafa.com/asset/clinuvel-pharmaceuticals-ltd-6512-cuv.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=cuv.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/clinuvel-pharm</span><span class="invisible">aceuticals-ltd-6512-cuv.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=cuv.asx</span></a></p>
ASX Mkt. Sensitive<p>Orthocell ( <a href="https://mastodon-grafa.social/tags/OCC" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>OCC</span></a> ) has released " First Sales of Striate in Germany, Austria & Swiss Region " on Wed 26 Mar at 09:02 AEST <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <br><a href="https://grafa.com/asset/orthocell-ltd-177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/orthocell-ltd-</span><span class="invisible">177-occ.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=occ.asx</span></a></p>
US News in English<p>Kezar Life Sciences reports positive results for zetomipzomib and 2024 fina... - published 25 Mar 2025 <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <br><a href="https://grafa.com/news/health-kezar-life-sciences-reports-positive-results-for-zetomipzomib-and-2024-financials-405779?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=405779" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-kezar-li</span><span class="invisible">fe-sciences-reports-positive-results-for-zetomipzomib-and-2024-financials-405779?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=405779</span></a></p>
ASX News in English<p>Regal Partners slashes Opthea investment value after trial setback - published 25 Mar 2025 <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <a href="https://mastodon-grafa.social/tags/TradingHalt" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>TradingHalt</span></a> <br><a href="https://grafa.com/news/health-regal-partners-slashes-opthea-investment-value-after-trial-setback-405002?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=405002" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-regal-pa</span><span class="invisible">rtners-slashes-opthea-investment-value-after-trial-setback-405002?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=405002</span></a></p>
Europe Says<p><a href="https://www.europesays.com/1940136/" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="">europesays.com/1940136/</span><span class="invisible"></span></a> What is glioblastoma, the aggressive brain cancer that killed former US Rep. Mia Love? <a href="https://pubeurope.com/tags/america" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>america</span></a> <a href="https://pubeurope.com/tags/BarackObama" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BarackObama</span></a> <a href="https://pubeurope.com/tags/BeauBiden" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BeauBiden</span></a> <a href="https://pubeurope.com/tags/BrainCancer" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BrainCancer</span></a> <a href="https://pubeurope.com/tags/cancer" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>cancer</span></a> <a href="https://pubeurope.com/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://pubeurope.com/tags/DonaldTrump" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>DonaldTrump</span></a> <a href="https://pubeurope.com/tags/GeneralNews" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>GeneralNews</span></a> <a href="https://pubeurope.com/tags/health" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>health</span></a> <a href="https://pubeurope.com/tags/JoeBiden" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>JoeBiden</span></a> <a href="https://pubeurope.com/tags/JohnMcCain" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>JohnMcCain</span></a> <a href="https://pubeurope.com/tags/MiaLove" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MiaLove</span></a> <a href="https://pubeurope.com/tags/MiaLoveWhat" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MiaLoveWhat</span></a> <a href="https://pubeurope.com/tags/NCStateWire" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NCStateWire</span></a> <a href="https://pubeurope.com/tags/Politics" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Politics</span></a> <a href="https://pubeurope.com/tags/RobertTisch" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>RobertTisch</span></a> <a href="https://pubeurope.com/tags/SaltLakeCity" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>SaltLakeCity</span></a> <a href="https://pubeurope.com/tags/U" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>U</span></a>.S.News <a href="https://pubeurope.com/tags/UnitedStates" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStates</span></a> <a href="https://pubeurope.com/tags/UnitedStatesHouseOfRepresentatives" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStatesHouseOfRepresentatives</span></a> <a href="https://pubeurope.com/tags/UnitedStatesOfAmerica" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStatesOfAmerica</span></a> <a href="https://pubeurope.com/tags/US" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>US</span></a> <a href="https://pubeurope.com/tags/USNews" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>USNews</span></a> <a href="https://pubeurope.com/tags/USTopics" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>USTopics</span></a> <a href="https://pubeurope.com/tags/USA" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>USA</span></a> <a href="https://pubeurope.com/tags/USANews" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>USANews</span></a> <a href="https://pubeurope.com/tags/UTStateWire" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UTStateWire</span></a> <a href="https://pubeurope.com/tags/Utah" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Utah</span></a> <a href="https://pubeurope.com/tags/YasmeenRauf" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>YasmeenRauf</span></a></p>
ASX News in English<p>Immutep doses first patient in Phase 3 TACTI-004 trial for advanced lung ca... - published 24 Mar 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/live" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>live</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <br><a href="https://grafa.com/news/health-immutep-doses-first-patient-in-phase-3-tacti-004-trial-for-advanced-lung-cancer-404957?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=404957" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-immutep-</span><span class="invisible">doses-first-patient-in-phase-3-tacti-004-trial-for-advanced-lung-cancer-404957?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=404957</span></a></p>
ASX Mkt. Sensitive<p>EBR Systems ( <a href="https://mastodon-grafa.social/tags/EBR" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>EBR</span></a> ) has released " 2024 Activity Report and Form 10-K submission " on Tue 25 Mar at 08:48 AEST <a href="https://mastodon-grafa.social/tags/NYSE" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NYSE</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/media" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>media</span></a> <a href="https://mastodon-grafa.social/tags/Strategy" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategy</span></a> <br><a href="https://grafa.com/asset/ebr-systems-inc-cdr-6751-ebr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=ebr.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/ebr-systems-in</span><span class="invisible">c-cdr-6751-ebr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=ebr.asx</span></a></p>
Hacker News<p>Eli Lilly will soon release key data on its weight loss pill orforglipron</p><p><a href="https://www.cnbc.com/2025/03/24/eli-lilly-to-release-weight-loss-pill-orforglipron-trial-data-.html" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://www.</span><span class="ellipsis">cnbc.com/2025/03/24/eli-lilly-</span><span class="invisible">to-release-weight-loss-pill-orforglipron-trial-data-.html</span></a></p><p><a href="https://mastodon.social/tags/HackerNews" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>HackerNews</span></a> <a href="https://mastodon.social/tags/EliLilly" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>EliLilly</span></a> <a href="https://mastodon.social/tags/Orforglipron" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Orforglipron</span></a> <a href="https://mastodon.social/tags/WeightLoss" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>WeightLoss</span></a> <a href="https://mastodon.social/tags/Pill" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Pill</span></a> <a href="https://mastodon.social/tags/HealthInnovation" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>HealthInnovation</span></a> <a href="https://mastodon.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a></p>
US News in English<p>UNITY Biotechnology announces positive Phase 2b trial results for UBX1325 i... - published 24 Mar 2025 <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <a href="https://mastodon-grafa.social/tags/BioTech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>BioTech</span></a> <a href="https://mastodon-grafa.social/tags/Grafa" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grafa</span></a> <a href="https://mastodon-grafa.social/tags/Technology" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Technology</span></a> <br><a href="https://grafa.com/news/health-unity-biotechnology-announces-positive-phase-2b-trial-results-for-ubx1325-in-diabetic-macular-edema-404715?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=404715" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-unity-bi</span><span class="invisible">otechnology-announces-positive-phase-2b-trial-results-for-ubx1325-in-diabetic-macular-edema-404715?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=404715</span></a></p>
US News in English<p>Clearmind Medicine's novel AUD drug candidate, CMND-100, arrives in the U.S... - published 24 Mar 2025 <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/UnitedStates" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStates</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Tech" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Tech</span></a> <a href="https://mastodon-grafa.social/tags/Strategic" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Strategic</span></a> <br><a href="https://grafa.com/news/health-clearmind-medicine-s-novel-aud-drug-candidate--cmnd-100--arrives-in-the-u-s--for-fda-approved-trial-404675?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=404675" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-clearmin</span><span class="invisible">d-medicine-s-novel-aud-drug-candidate--cmnd-100--arrives-in-the-u-s--for-fda-approved-trial-404675?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=404675</span></a></p>
ASX News in English<p>Opthea's COAST Phase 3 trial fails to meet primary endpoint - published 24 Mar 2025 <a href="https://mastodon-grafa.social/tags/trading" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>trading</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <br><a href="https://grafa.com/news/health-opthea-s-coast-phase-3-trial-fails-to-meet-primary-endpoint-404113?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=404113" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-opthea-s</span><span class="invisible">-coast-phase-3-trial-fails-to-meet-primary-endpoint-404113?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=404113</span></a></p>
Politico.eu (Unofficial RSS)America’s global AIDS relief program is on the brink <a href="https://www.politico.com/news/2025/03/23/syndicate-americas-global-aids-relief-program-is-on-the-brink-00244106?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS_Syndication" rel="nofollow noopener noreferrer" target="_blank">https://www.politico.com/news/2025/03/23/syndicate-americas-global-aids-relief-program-is-on-the-brink-00244106?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS_Syndication</a> <a class="hashtag" href="https://social.espeweb.net/tag/clinicaltrials" rel="nofollow noopener noreferrer" target="_blank">#Clinicaltrials</a> <a class="hashtag" href="https://social.espeweb.net/tag/communications" rel="nofollow noopener noreferrer" target="_blank">#Communications</a> <a class="hashtag" href="https://social.espeweb.net/tag/globalhealth" rel="nofollow noopener noreferrer" target="_blank">#Globalhealth</a> <a class="hashtag" href="https://social.espeweb.net/tag/publichealth" rel="nofollow noopener noreferrer" target="_blank">#Publichealth</a> <a class="hashtag" href="https://social.espeweb.net/tag/department" rel="nofollow noopener noreferrer" target="_blank">#Department</a> <a class="hashtag" href="https://social.espeweb.net/tag/investment" rel="nofollow noopener noreferrer" target="_blank">#Investment</a> <a class="hashtag" href="https://social.espeweb.net/tag/prevention" rel="nofollow noopener noreferrer" target="_blank">#Prevention</a> <a class="hashtag" href="https://social.espeweb.net/tag/healthcare" rel="nofollow noopener noreferrer" target="_blank">#HealthCare</a> <a class="hashtag" href="https://social.espeweb.net/tag/abortion" rel="nofollow noopener noreferrer" target="_blank">#Abortion</a> <a class="hashtag" href="https://social.espeweb.net/tag/advocacy" rel="nofollow noopener noreferrer" target="_blank">#Advocacy</a> <a class="hashtag" href="https://social.espeweb.net/tag/americas" rel="nofollow noopener noreferrer" target="_blank">#Americas</a> <a class="hashtag" href="https://social.espeweb.net/tag/payments" rel="nofollow noopener noreferrer" target="_blank">#Payments</a> <a class="hashtag" href="https://social.espeweb.net/tag/pentagon" rel="nofollow noopener noreferrer" target="_blank">#Pentagon</a> <a class="hashtag" href="https://social.espeweb.net/tag/security" rel="nofollow noopener noreferrer" target="_blank">#Security</a> <a class="hashtag" href="https://social.espeweb.net/tag/services" rel="nofollow noopener noreferrer" target="_blank">#Services</a> <a class="hashtag" href="https://social.espeweb.net/tag/vaccines" rel="nofollow noopener noreferrer" target="_blank">#Vaccines</a> <a class="hashtag" href="https://social.espeweb.net/tag/africa" rel="nofollow noopener noreferrer" target="_blank">#Africa</a> <a class="hashtag" href="https://social.espeweb.net/tag/budget" rel="nofollow noopener noreferrer" target="_blank">#Budget</a> <a class="hashtag" href="https://social.espeweb.net/tag/courts" rel="nofollow noopener noreferrer" target="_blank">#Courts</a> <a class="hashtag" href="https://social.espeweb.net/tag/policy" rel="nofollow noopener noreferrer" target="_blank">#Policy</a> <a class="hashtag" href="https://social.espeweb.net/tag/fraud" rel="nofollow noopener noreferrer" target="_blank">#Fraud</a> <a class="hashtag" href="https://social.espeweb.net/tag/us" rel="nofollow noopener noreferrer" target="_blank">#us</a>
Dining & Cooking<p>Dietary advanced glycation end-products and their associations with body weight on a Mediterranean diet and low-fat vegan diet: a randomized, cross-over trial <a href="https://www.diningandcooking.com/1972213/dietary-advanced-glycation-end-products-and-their-associations-with-body-weight-on-a-mediterranean-diet-and-low-fat-vegan-diet-a-randomized-cross-over-trial/" rel="nofollow noopener noreferrer" target="_blank"><span class="invisible">https://www.</span><span class="ellipsis">diningandcooking.com/1972213/d</span><span class="invisible">ietary-advanced-glycation-end-products-and-their-associations-with-body-weight-on-a-mediterranean-diet-and-low-fat-vegan-diet-a-randomized-cross-over-trial/</span></a> <a href="https://vive.im/tags/AdvancedGlyca" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>AdvancedGlyca</span></a>�onEndProducts;BMI <a href="https://vive.im/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a>.govNumber <a href="https://vive.im/tags/diet" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>diet</span></a> <a href="https://vive.im/tags/Mediterranean" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Mediterranean</span></a> <a href="https://vive.im/tags/MediterraneanVeganDiet" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MediterraneanVeganDiet</span></a> <a href="https://vive.im/tags/MediterraneanVegetarianRecipes" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>MediterraneanVegetarianRecipes</span></a> <a href="https://vive.im/tags/NCT03698955AdvancedGlyca" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>NCT03698955AdvancedGlyca</span></a>�onEndProducts <a href="https://vive.im/tags/Nutrion" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Nutrion</span></a> <a href="https://vive.im/tags/Vegan" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Vegan</span></a> <a href="https://vive.im/tags/VeganMediterraneanDiet" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>VeganMediterraneanDiet</span></a> <a href="https://vive.im/tags/VegetarianMediterraneanRecipes" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>VegetarianMediterraneanRecipes</span></a> <a href="https://vive.im/tags/WeightAbbrevia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>WeightAbbrevia</span></a>�ons:AGEs</p>
US News in English<p>BioXcel Therapeutics reports 50% enrollment milestone in SERENITY At-Home P... - published 21 Mar 2025 <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/ArtificialIntelligence" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ArtificialIntelligence</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Grafa" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Grafa</span></a> <a href="https://mastodon-grafa.social/tags/Nasdaq" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Nasdaq</span></a> <br><a href="https://grafa.com/news/health-bioxcel-therapeutics-reports-50--enrollment-milestone-in-serenity-at-home-phase-3-trial-for-bxcl501-403462?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=403462" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/health-bioxcel-</span><span class="invisible">therapeutics-reports-50--enrollment-milestone-in-serenity-at-home-phase-3-trial-for-bxcl501-403462?utm_source=us_news_en&utm_medium=mastodon&utm_campaign=403462</span></a></p>
ASX News in English<p>Anteris Technologies reports one-year results for DurAVR THV, eyes FDA appr... - published 21 Mar 2025 <a href="https://mastodon-grafa.social/tags/Mining" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Mining</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/ltd" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ltd</span></a> <a href="https://mastodon-grafa.social/tags/ASX" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ASX</span></a> <a href="https://mastodon-grafa.social/tags/price" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>price</span></a> <br><a href="https://grafa.com/news/mining-anteris-technologies-reports-one-year-results-for-duravr-thv--eyes-fda-approval-402718?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=402718" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/news/mining-anteris-</span><span class="invisible">technologies-reports-one-year-results-for-duravr-thv--eyes-fda-approval-402718?utm_source=asx_news_en&utm_medium=mastodon&utm_campaign=402718</span></a></p>
ASX Mkt. Sensitive<p>Anteris Technologies ( <a href="https://mastodon-grafa.social/tags/AVR" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>AVR</span></a> ) has released " Anteris Reports One-Year Patient Outcomes for DurAVR THV " on Fri 21 Mar at 09:33 AEST <a href="https://mastodon-grafa.social/tags/today" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>today</span></a> <a href="https://mastodon-grafa.social/tags/Facebook" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Facebook</span></a> <a href="https://mastodon-grafa.social/tags/UnitedStates" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>UnitedStates</span></a> <a href="https://mastodon-grafa.social/tags/ClinicalTrials" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>ClinicalTrials</span></a> <a href="https://mastodon-grafa.social/tags/Australia" class="mention hashtag" rel="nofollow noopener noreferrer" target="_blank">#<span>Australia</span></a> <br><a href="https://grafa.com/asset/anteris-technologies-ltd-687-avr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=avr.asx" rel="nofollow noopener noreferrer" translate="no" target="_blank"><span class="invisible">https://</span><span class="ellipsis">grafa.com/asset/anteris-techno</span><span class="invisible">logies-ltd-687-avr.asx?utm_source=asxmktsensitive&utm_medium=mastodon&utm_campaign=avr.asx</span></a></p>
ExploreLive feeds
Mastodon is the best way to keep up with what's happening.
Follow anyone across the fediverse and see it all in chronological order. No algorithms, ads, or clickbait in sight.
Create accountLoginDrag & drop to upload